Immunogenicity and safety of the non-typable Haemophilus influenzae- Moraxella catarrhalis (NTHi-Mcat) vaccine administered following the recombinant zoster vaccine versus administration alone: Results from a randomized, phase 2a, non-inferiority trialClinical Trial Published on 2023-12-312023-06-01 Journal: Human vaccines & immunotherapeutics [Category] 두창, 수두, 홍역, [키워드] Adjuvant system AS01 chronic obstructive pulmonary disease immune response Moraxella catarrhalis non-inferiority non-typable Haemophilus influenzae Recombinant zoster vaccine. [DOI] 10.1080/21645515.2023.2187194 PMC 바로가기 [Article Type] Clinical Trial
Effectiveness, safety, and immunogenicity of half dose ChAdOx1 nCoV-19 COVID-19 Vaccine: Viana projectArticle Published on 2022-08-292022-11-15 Journal: Frontiers in Immunology [Category] 진단, [키워드] adverse event age and sex analyzed anti-SARS-CoV-2 baseline Biomarker booster dose ChAdOx1 ChAdOx1 nCoV-19 ChAdOx1 nCoV-19 vaccine chemiluminescence chemokines Concentration Controlled trial COVID-19 Cytokines death dose effective Effectiveness evaluated exclusion first dose Fractional dose Frequency geometric mean Growth factors healthcare worker Hospitalization immune response immunization immunoassay immunogenic immunogenicity incidence incidence rate increase in indicate individual individuals multiplex neutralizing antibody non-inferiority non-randomized plaque reduction neutralization plasma pre-immune primary endpoint PRNT Protein quantified RBD Receptor binding domain Registered reported RT-PCR Safe Safety second dose Serious Adverse Event seroconversion rate seronegative seropositive seropositive subject SUS Vaccine vaccine. Vaccines [DOI] 10.3389/fimmu.2022.966416 PMC 바로가기
Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine (CoronaVac) co-administered with an inactivated quadrivalent influenza vaccine: A randomized, open-label, controlled study in healthy adults aged 18 to 59 years in China비활성화된 4가 인플루엔자 백신과 함께 투여된 SARS-CoV-2 비활성화된 백신(CoronaVac)의 면역원성 및 안전성: 중국에서 18세에서 59세 사이의 건강한 성인을 대상으로 한 무작위, 공개, 대조 연구Randomized Controlled Trial Published on 2022-08-262022-09-12 Journal: Vaccine [Category] COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] 95% confidence interval administration Adverse reaction antibody assigned China comparable Concomitant Concomitant administration conducted CoronaVac COVID-19 COVID-19 vaccine dose enrolled Evidence feasible first dose GMT groups healthy immune response immunogenicity inactivated Inactivated vaccine Influenza influenza vaccine Mild moderate MOST non-inferiority Occurrence Open-label participant per-protocol randomization Randomized Randomly receive regimen SARS-CoV-2 SARS-CoV-2. Seasonal influenza second dose seroconversion rate two-sided Vaccine Zhejiang [DOI] 10.1016/j.vaccine.2022.07.021 PMC 바로가기 [Article Type] Randomized Controlled Trial
Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine (Sinopharm BBIBP-CorV) coadministered with quadrivalent split-virion inactivated influenza vaccine and 23-valent pneumococcal polysaccharide vaccine in China: A multicentre, non-inferiority, open-label, randomised, controlled, phase 4 trial중국에서 4가 스플릿-비리온 비활성화 인플루엔자 백신 및 23가 폐렴구균 다당류 백신과 함께 투여된 비활성화 SARS-CoV-2 백신(Sinopharm BBIBP-CorV)의 면역원성 및 안전성: 다기관, 비열등성, 공개 라벨, 무작위, 통제, 4상 시험Clinical Trial Published on 2022-08-262022-09-12 Journal: Vaccine [Category] COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] 23-valent pneumococcal polysaccharide vaccine Administered antibody assigned BBIBP-CorV block randomization blood sample China Coadministration Community dose eligible GMC GMT GMT ratio had no IgG antibody immunogenicity inactivated Inactivated SARS-CoV-2 vaccine individual Influenza Influenza virus multicentre non-inferiority Open-label participant per-protocol population pneumococcal Pneumonia polysaccharide polysaccharide vaccine randomised randomised controlled trial Randomly recruited Registered Safe SARS-CoV-2 SARS-CoV-2 neutralising antibody SARS-CoV-2 vaccine seroconversion rate serotypes Sinopharm Split-virion inactivated influenza vaccine. strain stratified Streptococcus pneumoniae the SARS-CoV-2 three group Trial vaccination Vaccine vaccine group [DOI] 10.1016/j.vaccine.2022.07.033 PMC 바로가기 [Article Type] Clinical Trial
Effectiveness and adherence to closed face shields in the prevention of COVID-19 transmission: a non-inferiority randomized controlled trial in a middle-income setting (COVPROSHIELD)COVID-19 전염 예방에 대한 폐쇄형 안면 보호구의 효과 및 준수: 중간 소득 환경에서의 비열등 무작위 대조 시험(COVPROSHIELD)Randomized Controlled Trial Published on 2022-08-202022-09-11 Journal: Trials [Category] SARS, 임상, 치료기술, [키워드] 95% CI active control group Antibody test assigned benefit Chain Reaction clinical clinical trial Closed face shield combined use Community condition COVID-19 COVID-19 pandemic cross crowding determine disease Effectiveness face Face mask Face masks Face shield Follow-up follow-up period groups highly active IgM antibody inferiority intention-to-treat analysis intervention group limit Mask Masks mitigate non-inferiority Open-label participant per-protocol analysis polymerase chain polymerase chain reaction positive Prevent prevention of COVID-19 Primary outcome Randomized Randomized controlled trial Randomly reverse transcription risk risk difference SARS-CoV-2 SARS-CoV-2 detection SARS-COV-2 infection SARS-CoV-2 test SARS-CoV-2 transmission SARS-CoV-2. setting Spread surgical test result two groups Ventilation Viral transmission [DOI] 10.1186/s13063-022-06606-0 PMC 바로가기 [Article Type] Randomized Controlled Trial
Are micro enemas administered with a squeeze tube and a 5 cm-long nozzle as good or better than micro enemas administered with a 10 cm-long catheter attached to a syringe in people with a recent spinal cord injury? A non-inferiority, crossover randomised controlled trial Research Published on 2022-07-272022-10-05 Journal: Spinal cord [Category] 임상, [키워드] 95% confidence interval Administered assigned blind blinded bowel Care Complete determine hospital non-inferiority non-inferiority margin objective outcome Primary outcome Quality of life randomised controlled trial Randomly reflected reported Result secondary secondary outcome Secondary outcomes sequence setting Spinal cord injury Treatment Treatment effectiveness were measured [DOI] 10.1038/s41393-022-00835-5 [Article Type] Research
Early identification and severity prediction of acute respiratory infection (ESAR): a study protocol for a randomized controlled trial급성 호흡기 감염(ESAR)의 조기 식별 및 중증도 예측: 무작위 대조 시험을 위한 연구 프로토콜Article Published on 2022-07-202022-09-11 Journal: BMC Infectious Diseases [Category] COVID19(2023년), SARS, 임상, [키워드] 1:1 Acute respiratory infection alarm ARI both groups Clinical diagnosis clinical manifestations clinical trial Consensus Diagnosis diagnostic Efficacy Endpoint enrolled event group Hospitalization in both groups incidence include mechanical ventilation mNGS. multicenter Multiplex PCR non-inferiority Open-label outbreak oxygen participant pathway Patient primary endpoint Prognosis Randomized Randomized controlled trial Randomized controlled trials reached receive resource respiratory infection SARS-CoV-2 secondary Secondary endpoints Severe infection severity Study protocol tested Treatment Treatment outcome Treatment strategies two group two groups [DOI] 10.1186/s12879-022-07552-7 PMC 바로가기 [Article Type] Article
How effective are chest compressions when wearing mask? A randomised simulation study among first-year health care students during the COVID-19 pandemicRandomized Controlled Trial Published on 2022-05-082022-10-05 Journal: BMC Emergency Medicine [Category] 임상, [키워드] Analysis Care Chest Chest compressions collected conducted COVID-19 COVID-19 pandemic CPR decrease effective Effectiveness ERC evaluate fatigue group Health Health care Health care students in both group interval intervals non-inferiority participant participated Personal protective equipment provided questionnaire randomised Randomized Significant significant difference significantly Simulation surgical vital parameters was measured wearing Wearing mask. [DOI] 10.1186/s12873-022-00636-2 PMC 바로가기 [Article Type] Randomized Controlled Trial
Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trialmRNA-1273 부스터 후 SARS-CoV-2에 대한 면역 반응: 공개 표지 2상 시험Clinical Trial Published on 2022-05-012022-09-11 Journal: Nature Medicine [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, 치료기술, [키워드] 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Adverse reactions anti-Spike IgG antibody Antibody titer Antibody titers B.1.617.2 booster booster dose booster injection Booster vaccine Breakthrough infection caused Cell coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 criterion delta variant disease dose Effectiveness elicited ELISA evaluated exploratory follow-up period Frequency immunized immunogenicity individual Infection injection Local memory B memory B cell Meso Scale Discovery mRNA mRNA-1273 MSD NAb NAb titers neutralizing antibody non-inferiority non-randomized Open-label participant Phase 2 phase 2 trial Phase 3 primary immunogenicity raised reported respiratory Safe SARS-CoV-2 second dose Serious Adverse Event Serious Adverse Events severe acute respiratory syndrome Coronavirus significantly higher statistically systemic adverse reaction systemic adverse reactions titers vaccination Vaccine variants wild-type SARS-CoV-2 [DOI] 10.1038/s41591-022-01739-w PMC 바로가기 [Article Type] Clinical Trial
Study protocol for a modified antenatal care program for pregnant women with a low risk for adverse outcomes-a stepped wedge cluster non-inferiority randomized trial부작용 위험이 낮은 임산부를 위한 수정된 산전 관리 프로그램에 대한 연구 프로토콜-단계적 쐐기형 클러스터 비열등성 무작위 시험Article Published on 2022-04-082022-09-11 Journal: BMC Pregnancy and Childbirth [Category] 임상, [키워드] adverse events adverse outcome adverse outcomes Antenatal antenatal care Care Caregiver Caregiver satisfaction caused changed Cluster condition Course Data collection e-health. eight expected Health Health care Health care system health economics healthy implementation in-person visit include ISRCTN ISRCTN registry knowledge Low risk pregnancy majority Maternal Maternal outcomes midwife Neonatal Neonatal outcomes non-inferiority non-inferiority trial Obstetric outcomes pandemic Patient Patient satisfaction performed pregnant women protocol questionnaire Questionnaires Randomized randomized trial receive reduced Registered replaced REPLACED BY Research risk Risk assessment shift Study protocol Swedish Trial Virtual care women [DOI] 10.1186/s12884-022-04406-7 PMC 바로가기 [Article Type] Article